Related references
Note: Only part of the references are listed.Clinical and radiological profile of patients with spinal muscular atrophy type 4
P. V. S. Souza et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
Feeding difficulties in children and adolescents with spinal muscular atrophy type 2
Renske Wadman et al.
NEUROMUSCULAR DISORDERS (2021)
Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)
Lucas Mix et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study
Melanie Annoussamy et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic increment 7SMA mice
Kaitlyn M. Kray et al.
NEUROBIOLOGY OF DISEASE (2021)
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa Chand et al.
JOURNAL OF HEPATOLOGY (2021)
Nusinersen treatment of spinal muscular atrophy type 1-results of expanded access programme in Poland
Sandra Modrzejewska et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2021)
Risdiplam in Type 1 Spinal Muscular Atrophy
Giovanni Baranello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
Deepa H. Chand et al.
JOURNAL OF PEDIATRICS (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Meaghan Van Alstyne et al.
NATURE NEUROSCIENCE (2021)
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Katharina Vill et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
Anna Lusakowska et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Jerry R. Mendell et al.
JAMA NEUROLOGY (2021)
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1
Kelly F. Oechsel et al.
MUSCLE & NERVE (2021)
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
Karolina Aragon-Gawinska et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2020)
Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Amy G. Feldman et al.
JOURNAL OF PEDIATRICS (2020)
Longitudinal natural history of type I spinal muscular atrophy: a critical review
Eugenio Mercuri et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
Janbernd Kirschner et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2020)
Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec
Susan E. Matesanz et al.
JOURNAL OF CHILD NEUROLOGY (2020)
Clinical Variability in Spinal Muscular Atrophy TypeIII
Giorgia Coratti et al.
ANNALS OF NEUROLOGY (2020)
Combination molecular therapies for type 1 spinal muscular atrophy
Yohei Harada et al.
MUSCLE & NERVE (2020)
Spinal muscular atrophy - insights and challenges in the treatment era
Eugenio Mercuri et al.
NATURE REVIEWS NEUROLOGY (2020)
Impact of a national population-based carrier-screening program on spinal muscular atrophy births
Sharon Aharoni et al.
NEUROMUSCULAR DISORDERS (2020)
Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes
Megan A. Waldrop et al.
PEDIATRICS (2020)
RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design
Richard S. Finkel et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study
A. M. B. van der Heul et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Nusinersen in later-onset spinalmuscular atrophy Long-term results from the phase 1/2 studies
Basil T. Darras et al.
NEUROLOGY (2019)
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy
Linda P. Lowes et al.
PEDIATRIC NEUROLOGY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
Tamara Dangouloff et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy
Samiah Al-Zaidy et al.
PEDIATRIC PULMONOLOGY (2019)
Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
Maite Calucho et al.
NEUROMUSCULAR DISORDERS (2018)
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy
Roberto De Sanctis et al.
NEUROMUSCULAR DISORDERS (2018)
Therapy for Spinal Muscular Atrophy
Heather T. Whittaker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sleep disorders in spinal muscular atrophy
Maria C. Pera et al.
SLEEP MEDICINE (2017)
Natural history of infantile-onset spinal muscular atrophy
Stephen J. Kolb et al.
ANNALS OF NEUROLOGY (2017)
Emerging Therapies and Challenges in Spinal Muscular Atrophy
Michelle A. Farrar et al.
ANNALS OF NEUROLOGY (2017)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene
Afrooz Rashnonejad et al.
MOLECULAR BIOTECHNOLOGY (2016)
Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates
Kathrin Meyer et al.
MOLECULAR THERAPY (2015)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72 400 specimens
Elaine A. Sugarman et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2012)
Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice
Elisa Dominguez et al.
HUMAN MOLECULAR GENETICS (2011)
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Marco A. Passini et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery
Adam K. Bevan et al.
HUMAN MOLECULAR GENETICS (2010)
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2010)
Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons
Sandra Duque et al.
MOLECULAR THERAPY (2009)
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2009)
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Arthur H. M. Burghes et al.
NATURE REVIEWS NEUROSCIENCE (2009)
The Hammersmith functional score correlates with the SMN2 copy number:: A multicentric study
F. D. Tiziano et al.
NEUROMUSCULAR DISORDERS (2007)
Natural history of denervation in SMA:: Relation to age, SMN2 copy number, and function
KJ Swoboda et al.
ANNALS OF NEUROLOGY (2005)
Intelligence and cognitive function in children and adolescents with spinal muscular atrophy
A von Gontard et al.
NEUROMUSCULAR DISORDERS (2002)
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
MD Mailman et al.
GENETICS IN MEDICINE (2002)